Catyalyst (CPRX) Says CPP-109 Missed Phase IIb Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Catyalyst (CPRX) Slammed as CPP-109 Missed Primary Endpoint in Phase IIb
November 8, 2012 8:48 AM ESTCatyalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) shares are getting slammed Thursday morning following new results from its Phase IIb of CPP-109 on cocaine addiction treatment. The pharma said that CPP-109 missed its primary endpoint.
Shares are down about 60 percent upon resumption of trading. For more color, click here.... More
